Showing results (281-290 of 293) with videos related to
Sort By:
Pageof 30
British Journal of Cancer|December 10, 2021
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumoursPanagiotis A Konstantinopoulos, Su-Chun Cheng, Jeffrey G Supko, et al.JCO Precision Oncology|April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1Jun Gong, Alain C Mita, Zihan Wei, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2022
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984Joseph W Kim, Rana R McKay, Marc R Radke, et al.Proceedings of the National Academy of Sciences of the United States of America|November 6, 2013
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiationTracy T Batchelor, Elizabeth R Gerstner, Kyrre E Emblem, et al.Melanoma Research|March 4, 2021
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)Stergios J Moschos, Zeynep Eroglu, Nikhil I Khushalani, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2023
The New NCI Precision Medicine TrialsLyndsay N Harris, Charles D Blanke, Harry P Erba, et al.Cancer Chemotherapy and Pharmacology|April 18, 2022
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancerJulia Manzo, Shannon Puhalla, Shalu Pahuja, et al.Eclinicalmedicine|January 29, 2025
CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trialsJan Rekowski, Christina Guo, Olga Solovyeva, et al.Eclinicalmedicine|January 29, 2025
SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocolsMoreno Ursino, Guillermo Villacampa, Jan Rekowski, et al.Journal of the National Cancer Institute|April 28, 2020
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot StudyBarbara A Conley, Lou Staudt, Naoko Takebe, et al.Pageof 30